Evidence map›Paper›PMID 27438078›Full record

Trial reportPloS one2016

Specific Pharmacological Effects of Paroxetine Comprise Psychological but Not Somatic Symptoms of Depression.

Benjamin D Schalet, Tony Z Tang, Robert J DeRubeis, Steven D Hollon, Jay D Amsterdam, Richard C Shelton

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Benjamin D SchaletDepartment of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America.
Tony Z TangDepartment of Psychology, University of Pennsylvania, Philadelphia, PA, United States of America.
Robert J DeRubeisDepartment of Psychology, University of Pennsylvania, Philadelphia, PA, United States of America.
Steven D HollonDepartment of Psychology, Vanderbilt University, Nashville, TN, United States of America.
Jay D AmsterdamDepression Research Unit, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States of America.
Richard C SheltonDepartment of Psychiatry and Behavioral Neurobiology, The University of Alabama at Birmingham, Birmingham, AL, United States of America.
University of Pennsylvania · USNorthwestern University · USUniversity of Alabama at Birmingham · USVanderbilt University · US

Funding

Prevention of Recurrence in Depression with Drugs and CTK02MH001697 · NIMH · VANDERBILT UNIVERSITY · PI HOLLON, STEVEN DENNIS · 2000 to 2009
$1.2M
COGNITIVE THERAPY AND PHARMACOTHERAPY FOR DEPRESSIONR10MH055875 · NIMH · VANDERBILT UNIVERSITY · PI HOLLON, STEVEN D · 1996 to 2000
$231k
NIMH NIH HHS K02 MH001697NIMH NIH HHS R10 MH055875
6 · The paper itself

Abstract

backgroundMeta-analyses of placebo-controlled trials of SSRIs suggest that only a small portion of the observable change in depression may be attributed to "true" pharmacological effects. But depression is a multidimensional construct, so treatment effects may differ by symptom cluster. We tested the hypothesis that SSRIs uniquely alter psychological rather than somatic symptoms of depression and anxiety.

methodOutpatients with moderate to severe MDD were randomly assigned to receive paroxetine (n = 120) or placebo (n = 60).

resultsParoxetine significantly outperformed placebo on all psychological subscales of the syndrome measures, but not on any of the somatic subscales. The difference in score reduction between paroxetine and placebo was more than twice as great for the psychological symptoms compared to the somatic symptoms.

conclusionsParoxetine appears to have a "true" pharmacological effect on the psychological but not on the somatic symptoms of depression and anxiety. Paroxetine's influence on somatic symptoms appears to be mostly duplicated by placebo.

Indexed as

AnxietyDouble-Blind MethodFemaleHumansMajor Depressive DisorderMaleMedically Unexplained SymptomsNorepinephrineParoxetinePersonalityPsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSerotoninTreatment OutcomeNorepinephrineParoxetineSelective Serotonin Reuptake InhibitorsSerotonin

Identifiers

PMID27438078
PMCPMC4954666
OpenAlexW2486969762

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.